Tag Archives: John Newman

Canaccord Genuity Sticks to Its Buy Rating for Selecta Biosciences (SELB)

Canaccord Genuity analyst John Newman maintained a Buy rating on Selecta Biosciences (SELB – Research Report) yesterday and set a price target of $13.00. The company’s shares closed last Wednesday at $3.16. According to TipRanks.com, Newman is a 5-star analyst

Analysts Offer Insights on Healthcare Companies: Seres Therapeutics (NASDAQ: MCRB), Karyopharm Therapeutics (NASDAQ: KPTI) and Biodesix (NASDAQ: BDSX)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Seres Therapeutics (MCRB – Research Report), Karyopharm Therapeutics (KPTI – Research Report) and Biodesix (BDSX – Research Report) with bullish sentiments. Seres

Canaccord Genuity Keeps Their Buy Rating on Aileron Therapeutics (ALRN)

In a report issued on November 13, John Newman from Canaccord Genuity maintained a Buy rating on Aileron Therapeutics (ALRN – Research Report), with a price target of $5.00. The company’s shares closed last Friday at $1.05. According to TipRanks.com,

Analysts Offer Insights on Healthcare Companies: Kaleido Biosciences (NASDAQ: KLDO), Minerva Neurosciences (NASDAQ: NERV) and Rhythm Pharmaceuticals (NASDAQ: RYTM)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Kaleido Biosciences (KLDO – Research Report), Minerva Neurosciences (NERV – Research Report) and Rhythm Pharmaceuticals (RYTM – Research Report) with bullish sentiments.

Canaccord Genuity Reaffirms Their Buy Rating on Sesen Bio (SESN)

Canaccord Genuity analyst John Newman maintained a Buy rating on Sesen Bio (SESN – Research Report) yesterday and set a price target of $5.00. The company’s shares closed last Monday at $1.12. According to TipRanks.com, Newman is a 5-star analyst

Canaccord Genuity Reaffirms Their Buy Rating on ImmunoGen (IMGN)

In a report released yesterday, John Newman from Canaccord Genuity maintained a Buy rating on ImmunoGen (IMGN – Research Report), with a price target of $12.00. The company’s shares closed last Monday at $5.65. According to TipRanks.com, Newman is a